Children and adolescents who are wait-listed for lung transplantation and have the worst functional status are at the greatest risk…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
CFTR modulator therapies can enhance the ability of certain immune cells to kill bacteria, independent of defects in the CFTR…
A Chicago children’s hospital is leading an awareness campaign to reduce the missed or delayed diagnosis of cystic fibrosis…
One year of treatment with hypertonic saline, inhaled twice daily, reduced the thickness of the airway walls in children…
People with cystic fibrosis (CF) who were underweight before treatment gained the most weight after six months on…
Trikafta treatment for six months in people with cystic fibrosis (CF) was found in a real-world study to…
A1c, a test that measures the average levels of sugar in the bloodstream, was able to predict the future risk…
Researchers have identified a new class of CFTR correctors to treat cystic fibrosis (CF) that enhance the potency of…
A single dose of 4D Molecular Therapeutics’ 4D-710, an inhaled gene therapy candidate for adults with cystic fibrosis…
People with cystic fibrosis (CF) who frequently use healthcare resources accounted for almost one-half of total healthcare costs, according…